

## LIST OF ABBREVIATIONS

### 0-9

4HC .....hydroperoxycyclophosphamide  
13-cRA .....13-*cis* retinoic acid

### A

ABMTR .....Autologous Blood and Marrow Transplant  
Registry  
ABVD .....doxorubicin, bleomycin, vinblastine, dacarbazine  
ACD .....acid-citrate-dextrose  
ACIS .....Automated Cellular Imaging System  
AD .....autoimmune disease  
ADCC .....antibody-dependent cell toxicity  
AFM .....doxorubicin, fluorouracil, methotrexate  
AGC .....absolute granulocyte count  
AIDA .....all-*trans* retinoic acid, idarubicin  
AIDS .....acquired immunodeficiency syndrome  
AIHA .....autoimmune hemolytic anemia  
AITP .....autoimmune thrombocytopenic purpura  
ALL .....acute lymphoblastic leukemia  
alloBMT .....allogeneic bone marrow transplantation  
ALT .....alanine transaminase  
 $\alpha$ -MEM ..... $\alpha$ -minimal essential medium  
AML .....acute myeloblastic leukemia  
.....acute myeloid leukemia  
ANA .....antinuclear antibody  
ANC .....absolute neutrophil count  
APC .....antigen-presenting cell  
Ara-C .....cytosine arabinoside  
ASCO .....American Society of Clinical Oncology  
ASCR .....autologous stem cell rescue  
AST .....aspartate transaminase  
ATC .....activated T cell  
ATC .....adriamycin, paclitaxel, cyclophosphamide  
ATG .....antithymocyte globulin  
ATRA .....all-*trans* retinoic acid

AUC	.area under the curve
autoBMT	.autologous bone marrow transplantation
autoPBSCT	.autologous peripheral blood stem cell transplantation
autoSCT	.autologous stem cell transplantation

**B**

BAVC	.BCNU, amsacrine, idarubicin, cytosine arabinoside
BCAC	.breast cancer antibody cocktail
BCNU	.carmustine (nitrosourea)
BEACOPP	.bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone
BEAM	.BCNU, etoposide, cytosine arabinoside, melphalan
bFGF	.basic fibroblast growth factor
BFU-E	.burst forming unit-erythroid
BGF	.bovine growth hormone
BMC	.bone marrow cell
BMSC	.bone marrow stromal cells
BMT	.bone marrow transplantation
BNLI	.British National Lymphoma Investigation
BSA	.bovine serum albumin
BSO	.buthionine sulfoximine
BU CY	.busulfan, cyclophosphamide

**C**

CAE	.cyclophosphamide, doxorubicin, etoposide
CAF	.cyclophosphamide, doxorubicin, fluorouracil
CAFC	.cobblestone area-forming cell
CALGB	.Cancer and Leukemia Group B
CAT	.cyclophosphamide, adriamycin, paclitaxel
CAV	.cyclophosphamide, doxorubicin, vincristine
CAVe	.cyclophosphamide, adriamycin, etoposide
CBP	.cyclophosphamide, carmustine, cisplatin
CBVA	.cyclophosphamide, BCNU, etoposide, cytosine arabinoside
CCG	.Children's Cancer Group

CDDP	.cisplatin
CDR	.complementarity-determining region
CEM-LI	.carboplatin, etoposide, melphalan, and local irradiation
CFA	.complete Freund's adjuvant
CFC	.colony-forming cell
CFU-GM	.colony-forming unit-granulocyte/macrophage
CFU-S	.spleen colony-forming unit
cGMP	.current good manufacturing practices
cGTP	.current good tissue practices
CHOP	.cyclophosphamide, adriamycin, vincristine .cyclophosphamide, doxorubicin, vincristine, prednisone
CI	.confidence interval
CK	.cytokeratin
CLL	.chronic lymphocytic leukemia
CMA	.cyclophosphamide, mitoxantrone, melphalan
CMF	.cyclophosphamide, methotrexate, fluorouracil
CML	.chronic myelogenous leukemia .chronic myeloid leukemia
CM	.conditioned medium
CMF	.cyclophosphamide, methotrexate, fluorouracil
CMV	.cytomegalovirus
CODE	.cyclophosphamide, vincristine, doxorubicin, etoposide
COG	.Children's Oncology Group
COPP	.cyclophosphamide, vincristine, procarbazine, prednisone
CP	.chronic phase
CPB	.cyclophosphamide, BCNU, cisplatin
CPG	.cyclophosphamide, prednisone, G-CSF
CR	.complete remission .complete response
CRP	.C-reactive protein
CsA	.cyclosporine, cyclosporin A
CSF	.colony-stimulating factor
CT	.computed tomography
CTC	.Common Toxicity Criteria
CTC	.cyclophosphamide, thiotepa, carboplatin
CTL	.cytotoxic T lymphocyte
CTX	.cyclophosphamide

CVAD	.cyclophosphamide, vincristine, adriamycin
CVP	.cyclophosphamide, etoposide, cisplatin
CY	.cyclophosphamide
CYP450	.cytochrome P450

**D**

DAB	.3,3-diaminobenzidine
DC	.dendritic cell
DCEP	.dexamethasone, cyclophosphamide, etoposide, cisplatin
DCFH-DA	.2',7'-dichlorofluorescein-diacetate
DFS	.disease-free survival
DHAP	.dexamethasone, cytosine arabinoside, cisplatin
DLCO	.pulmonary carbon monoxide diffusing capacity
DLI	.donor leukocyte infusion .donor lymphocyte infusion
DM	.defined medium
DMEM	.Dulbecco's modified Eagle's medium
DMSO	.dimethylsulfoxide
DNA-PKcs	.DNA-protein kinase catalytic subunit
DSB	.double-stranded DNA break
dsDNA	.double-strand DNA
dsICC	.double-immunostaining immunocytochemical

**E**

EBDIS	.European Breast Dose Intensity Study
EBMT	.European Group for Blood and Marrow Transplantation
EBV	.Epstein-Barr virus
ECM	.extracellular matrix
ECOG	.Eastern Cooperative Oncology Group
ED	.extensive disease
EDSS	.expanded disability status scale
EFS	.event-free survival
EICC	.tumor-enriched immunocytochemical
ELISA	.enzyme-linked immunosorbent assay
E-LTC-IC	.extended long-term culture-initiating cell
EP	.etoposide, cisplatin
Epo	.erythropoietin

EPTS	.....	extension primer tag selection
ER	.....	estrogen receptor
ES	.....	Evans' syndrome
EULAR	.....	European League Against Rheumatism

**F**

FAB	.....	French-American-British
FAC	.....	fluorouracil, adriamycin, cyclophosphamide
FACS	.....	fluorescence-activated cell sorter/sorting
FAHCT	.....	Foundation for the Accreditation of Hematopoietic Cell Therapy
FCS	.....	fetal calf serum
FDA	.....	US Food and Drug Administration
FEV <sub>1</sub>	.....	1-second forced expiratory volume
FEC	.....	fluorouracil, epirubicin, cyclophosphamide
FFTF	.....	freedom from treatment failure
FITC	.....	fluorescein isothiocyanate
FLAG-Ida	.....	fludarabine, cytosine arabinoside, idarubicin
FLT	.....	Flt-3 ligand
FrC	.....	fragment C
FuMEP	.....	fluorouracil, mitomycin, etoposide, and cisplatin

**G**

GABG	.....	German Adjuvant Breast Cancer Study Group
G-CSF	.....	granulocyte colony-stimulating factor
GINECO	.....	Groupe Investigation National Etude Cancer Ovaive
GITMO	.....	Gruppo Italiano Trapianti di Midollo Osseo
GM-CFC	.....	granulocyte-macrophage colony-forming cell
GM-CSF	.....	granulocyte-macrophage colony-stimulating factor
GMP	.....	good manufacturing practices
GOG	.....	Gynecological Oncology Group
GTP	.....	good tissue practices
GVHD	.....	graft-vs.-host disease
GVL	.....	graft-vs.-leukemia
GVM	.....	graft vs. malignancy
	.....	graft vs. myeloma

**H**

HACA	.....	.human anti-chimeric antibody
HAMA	.....	.human anti-mouse antibody
HAQ	.....	.health assessment questionnaire
HBV	.....	.hepatitis B virus
HCV	.....	.hepatitis C virus
HD	.....	.high dose
	.....	.Hodgkin's disease
HDCT	.....	.high-dose chemotherapy
HDDCT	.....	.high-dose dense chemotherapy
HDIT	.....	.high-dose immunosuppressive therapy
HDS	.....	.high-dose sequential
HGF	.....	.hematopoietic growth factor
HHV	.....	.human herpes virus
HIV	.....	.human immunodeficiency virus
HPC	.....	.hematopoietic progenitor cell
HPP-CFC	.....	.high proliferative potential colony-forming cell
HPV	.....	.human papilloma virus
HS-GAG	.....	.heparin sulfate glycosaminoglycan
HSCT	.....	.hematopoietic stem cell transplantation
HTLV	.....	.human T-cell leukemia virus
HU	.....	.hydroxyurea

**I**

IBCSG	.....	.International Breast Cancer Study Group
IBMTR	.....	.International Blood and Marrow Transplant Registry
ICC	.....	.immunocytochemical
ICE	.....	.ifosfamide, carboplatin, etoposide
ICSI	.....	.intracytoplasmic sperm injection
Id	.....	.idiotypic
ID	.....	.induction chemotherapy
IDE	.....	.investigational device exemption
IFM	.....	.Intergroupe Français du Myelome
IFN	.....	.interferon
IFRT	.....	.involved-field radiation therapy
Ig	.....	.immunoglobulin
IL	.....	.interleukin

IMDM	.Iscove's modified Dulbecco's medium
IMiD	.immunomodulatory drug
IND	.investigational new drug
IP	.intraperitoneal
IPE	.ifosfamide, cisplatin, etoposide
IRB	.institutional review board
ISS	.immunostimulatory sequence
ITP	.idiopathic thrombocytopenic purpura
IV	.intravenous, intravenously
IVF	.in vitro fertilization

**J**

JCA	.juvenile chronic arthritis
JIA	.juvenile idiopathic arthritis

**K**

KS	.Kaposi's sarcoma
KLH	.keyhole limpet hemocyanin

**L**

LAK	.lymphocyte-activated killer
LD	.limited disease
	.low dose
LFS	.leukemia-free survival
LIF	.leukemia inhibitory factor
LM	.ligation mediated
LP	.leukapheresis product
LPS	.lipopolysaccharide
LTC-IC	.long-term culture-initiating cell
LTCM	.long-term culture medium
LVL	.large-volume leukapheresis

**M**

mAb	.monoclonal antibody
MACS	.magnetic cell separation
m-AMSA	.amsacrine
MAPK	.mitogen-activated protein kinase

MAS	.macrophage-activation syndrome
McCFUD	.cyclophosphamide, methotrexate, fluorouracil, dexamethasone, cisplatin
MCL	.mantle cell lymphoma
MCP	.monocyte chemoattractant protein
MCyR	.major cytogenetic remission
MDS	.myelodysplastic syndrome
MGDF	.megakaryocyte growth and development factor
MGF	.mast cell growth factor
mHA <sub>g</sub>	.minor histocompatibility antigen
MHC	.major histocompatibility complex
MIBG	.metaiodobenzylguanidine
MIP	.macrophage inflammatory protein
ML-IC	.myeloid/lymphoid-initiating cell
MLR	.mixed lymphocyte reaction
MLV	.murine leukemia virus
MM	.multiple myeloma
MMF	.mycophenolate mofetil
MNC	.mononuclear cell
MOPP	.mechlorethamine, vincristine, procarbazine, prednisone
MRC	.Medical Research Council
MRD	.minimal residual disease
MRI	.magnetic resonance imaging
MS	.multiple sclerosis
MTB	.mitoxantrone, thiotepa, BCNU
MTD	.maximum tolerated dose

**N**

NANT	.New Approaches to Neuroblastoma Therapy
NCI	.National Cancer Institute
NCIC-CTG	.National Cancer Institute of Canada Clinical Trials Group
NF $\kappa$ B	.nuclear factor $\kappa$ B
NHL	.non-Hodgkin's lymphoma
NIH	.National Institutes of Health
NIP	.noninfectious pulmonary
NK	.natural killer
NMDP	.National Marrow Donor Program
NS	.not significant

NST .....nonmyeloablative allogeneic stem cell  
transplantation

## O

OM .....occult metastasis  
ORR .....overall response rate  
OS .....overall survival

## P

PACE-BOM .....prednisone, doxorubicin, cyclophosphamide,  
etoposide, bleomycin, vincristine, methotrexate  
PB .....peripheral blood  
PBL .....peripheral blood lymphocyte  
PBMC .....peripheral blood mononuclear cell  
PBPC .....peripheral blood progenitor cell  
PBS .....phosphate-buffered saline  
PBSC .....peripheral blood stem cell  
PBSCT .....peripheral blood stem cell transplantation  
PCI .....prophylactic cranial irradiation  
PCL .....plasma cell leukemia  
PCR .....polymerase chain reaction  
PE .....phycoerythrin  
PF .....platelet factor  
PFS .....progression-free survival  
PGP 9.5 .....protein gene product 9.5  
Ph .....Philadelphia chromosome  
PLT .....platelet count  
PMA .....phorbol myristate acetate  
PMN .....polymorphonuclear cell  
pMS .....progressive multiple sclerosis  
PNET .....primitive neuroectodermal tumor  
PNH .....paroxysmal nocturnal hemoglobinuria  
PR .....partial remission  
.....partial response  
PRC .....packed red cells  
ProMACE-MOPP .....cyclophosphamide, etoposide, doxorubicin,  
nitrogen mustard, procarbazine, vincristine,  
high-dose methotrexate  
PSA .....prostate-specific antigen

PSCC .....peripheral stem cell collection

## **R**

RA .....rheumatoid arthritis  
 RAFTK .....related activated focal adhesion kinase  
 RCC .....renal cell carcinoma  
 RCT .....randomized controlled trial  
 REAL .....Revised European American Lymphoma  
 RFLP .....restriction fragment length polymorphism  
 RFS .....recurrence-free survival  
 rh .....recombinant human  
 RIT .....radioimmunotherapy  
 RR .....relative risk  
       .....risk of relapse  
 RSS .....Rodnan skin score  
 RT-PCR .....reverse transcription-polymerase chain reaction

## **S**

SAA .....severe aplastic anemia  
 SAD .....severe autoimmune disease  
 SAM .....sheep anti-mouse  
 SCF .....stem cell factor  
 scFv .....single-chain Fv  
 SCG .....stem cell graft  
 SCLC .....small cell lung cancer  
 SCT .....stem cell transplantation  
 SD .....standard deviation  
 SDCT .....standard-dose chemotherapy  
 SHP2 .....SH2-containing protein  
 SI .....stimulation index  
 SLE .....systemic lupus erythematosus  
 SLEDAI .....SLE disease activity index  
 SMH .....small marrow harvest  
 SRC .....SCID repopulating cell  
 SSc .....systemic sclerosis  
 STAMP V .....cyclophosphamide, thiotepa, carboplatin  
 SVL .....standard-volume leukapheresis  
 SWOG .....Southwest Oncology Group

**T**

TAA	.tumor-associated antigens
TBI	.total body irradiation
TCD	.T-cell depleted
TCR	.T-cell receptor
TGF	.transforming growth factor
Th	.T helper
TIP	.paclitaxel, ifosfamide, cisplatin
TLI	.total lymphoid irradiation
TNCs	.total nucleated cells
TNF	.tumor necrosis factor
TNI	.total nodal irradiation
TNT	.mitoxantrone, thiotepa, paclitaxel
TPO	.thrombopoietin
TREC	.T-cell receptor–rearrangement excision circle
TRM	.treatment-related mortality
	.transplant-related mortality
TRT	.thoracic radiotherapy
TSP	.thrombospondin
	.tropical spastic paraparesis
TTP	.thrombotic microangiopathy
	.time to progression

**U**

UCSF	.University of California San Francisco
URD	.unrelated donor

**V**

VAPEC-B	.vinblastine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin
VEGF	.vascular endothelial growth factor
VIC	.etoposide, ifosfamide, carboplatin
VGPR	.very good partial remission
VNTR	.variable number of tandem repeats
VOD	.veno-occlusive disease
VP-16	.etoposide

**W**

- WBC .....white blood cell count
- WHO .....World Health Organization
- WSG .....Westdeutsche Study Group

**X**

- XCIP .....X-chromosome inactivation pattern